(Q36576089)

15 August 2017

Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda (English)

1 reference

15 August 2017

0 references

0 references

1 reference

Harriet Mayanja-Kizza

object named as

Harriet Mayanja-Kizza

series ordinal

4

0 references

Edwin D Charlebois

series ordinal

7

object named as

Edwin D Charlebois

1 reference

15 August 2017

10

Diane V Havlir

1 reference

15 August 2017

2

Maria N Walusimbi

1 reference

15 August 2017

5

Roy D Mugerwa

1 reference

15 August 2017

9

Christopher C Whalen

1 reference

15 August 2017

8

W Henry Boom

1 reference

15 August 2017

1

Padmini Srikantiah

1 reference

15 August 2017

6

Royce Lin

1 reference

15 August 2017

H Kose Kayanja

3

1 reference

PMC publication ID

4752198

15 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

15 August 2017

1 reference

15 August 2017

21

1 reference

15 August 2017

14

1 reference

15 August 2017

1972-1974

1 reference

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Population-based hematologic and immunologic reference values for a healthy Ugandan population

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Performance of Immunologic Responses in Predicting Viral Load Suppression

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752198

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17721107

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAD.0B013E32823ECF6E

1 reference

15 August 2017

1 reference

PMC publication ID

4752198

15 August 2017

PubMed publication ID

17721107

1 reference

PMC publication ID

4752198